ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

NIPT Premaitha

9.10
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Premaitha LSE:NIPT London Ordinary Share GB00BN31ZD89 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 9.10 9.00 9.20 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Premaitha Share Discussion Threads

Showing 3926 to 3949 of 6500 messages
Chat Pages: Latest  164  163  162  161  160  159  158  157  156  155  154  153  Older
DateSubjectAuthorDiscuss
27/10/2016
07:25
27 Sept 2016 Shareprophets, Strong Buy
deanroberthunt
27/10/2016
07:23
'Despite short-term distractions caused by the infringement claims of Illumina, Premaitha is building a highly compelling business, which will be global within the next twelve months.'
timojelly
27/10/2016
07:22
Revenue first half of previous year £600k!
dave444
27/10/2016
07:21
target share price end 2018 75-100p
deanroberthunt
27/10/2016
07:20
'The international landscape for non-invasive prenatal testing is evolving very considerably in Premaitha's favour'
timojelly
27/10/2016
07:20
I believe this is a similar story to Tristel, which now has sales of nearly £20m, profits of £3-4m and pays a dividend.....sp has 7-8 bagged from year past lows in 2013...

NIPT, however, has far more potential imvho

deanroberthunt
27/10/2016
07:20
You would expect that - they did not sell much in the equivalent period last year!
dave444
27/10/2016
07:18
`I am pleased to note that trading in the first half of the current financial year was materially above the equivalent period last year, positioning Premaitha comfortably on track to outperform the IONA(R) test's first full commercial year.`
timojelly
27/10/2016
07:16
diamond in the AIM rough
deanroberthunt
27/10/2016
07:14
added some yesterday, hopefully, it doesn't bounce early doors, will add some more
deanroberthunt
27/10/2016
07:14
Cracking agm statement.

Bring on the newsflow

"We are very encouraged by the growth we have seen in the Middle East and we are focusing substantial efforts within this region and in Asia Pacific and hope to announce shortly a number of sizeable commercial agreements."

brainspark1
27/10/2016
07:14
cash flow positive early 2017
deanroberthunt
27/10/2016
07:12
Very very positive. READ It! Sub 20p will very soon be history.... Roll in 50p.
timojelly
27/10/2016
07:04
silly cheap, market is irrational, but not forever.....hold, live long and prosper.
deanroberthunt
27/10/2016
00:22
If you miss the AGM tomorrow but would like to meet the company and ask the CEO a few questions, Premaitha are presenting at the ShareSoc seminar in Leeds on the 3rd November - here's the link - hxxp://www.sharesoc.org/leeds-november.html
quinag
26/10/2016
17:33
Black - yes, do the opposite in most cases and he's worth following - imho.
gooosed
26/10/2016
16:34
Ah yes TW, a lot of people here quids down thanks to him.
blackss
26/10/2016
15:40
No one is admitting to attend the AGM (too ashamed?).

Hopefully there will be some feedback. There has been a lot of opinions expressed on all boards (mostly negative) so hope we don't just let the BOD just post 'all motions passed. At least TW will have plenty to say next week.

ewads
26/10/2016
11:21
Anyone attending AGM ?
gooosed
26/10/2016
08:40
when the case is sorted this'll be over 25p
deanroberthunt
25/10/2016
18:09
Illumina being investigated again..investors not happy it seems!






NEW YORK, Oct. 21, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Illumina Inc. ("Illumina" or the "Company") (NASDAQ: ILMN). Such investors are advised to contact Peretz Bronstein or his investor relations analyst Yael Hurwitz at info@bgandg.com or 212-697-6484.

The investigation concerns whether Illumina and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

hjb1
25/10/2016
16:28
Sequenom has prelim injunction filed today against Amedes (+1 other) in Germany related to their Fetalis NIPT test base on Ariosa technology.
Do we know if these guys are a Premaitha customer?

philburt
21/10/2016
14:30
More shares for the boys while Genoma is doing the heavy lifting.

Give them a good kicking at the AGM folks

hurricane.
21/10/2016
11:08
Your forgetting the shares at 6.5p and 8p that's over 40 mil plus
thinkbig?
Chat Pages: Latest  164  163  162  161  160  159  158  157  156  155  154  153  Older

Your Recent History

Delayed Upgrade Clock